Skip to content

HEMODEX study- Detralex* versus placebo in the treatment of acute hemorrhoids in patients with acute hemorrhoidal attack. One week, double-blind, randomized, placebo controlled, multicentre study. - HEMODEX

HEMODEX study- Detralex* versus placebo in the treatment of acute hemorrhoids in patients with acute hemorrhoidal attack. One week, double-blind, randomized, placebo controlled, multicentre study. - HEMODEX

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
EU CTR
Registry ID
EUCTR2004-002707-32-CZ
Enrollment
150
Registered
2004-11-03
Start date
2004-11-15
Completion date
Unknown
Last updated
2012-03-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute hemorrhoidal attack (stage I, II, III) taking no longer than 48 hours MedDRA version: 5.1 Level: PT Classification code 10019022

Interventions

Trade Name: DETRALEX Product Name: DETRALEX Product Code: S05682-F34 Pharmaceutical Form: Film-coated tablet INN or Proposed INN: N.A. CAS Number: N.A. Current Sponsor code: S05682-00 Other descriptiv

Sponsors

SERVIER s.r.o.
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Male and female adults between 18 and 60 years; presenting an acute hemorhoidal episode of recent onset (48 hours at maximum); established by anoscopy examination; stage I, II, III; presenting an bleeding with a grade of at least 3 - means blood on feces, in toilet bowl and/or anitis with a grade of at least 3 (moderate) on a four point scale rating from 1 to 4 at examination. Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) no F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria: Patient presenting hemorrhoidal manifestations requiring acute surgery; presenting hemorrhoidal associated with an anal fissure; presenting permanent prolapsed hemorrhoids (stage IV); patient having already received venotonics, anticoagulant, anti-platelet, analgetic or antiinflammatory treatment for ongoing episode; patient receiving topical hemorrhoid treatment for ongoing episode.

Design outcomes

Primary

MeasureTime frame
Main Objective: Comparison of anitis, bleeding (reduction of bleeding, time to stop bleeding) and pain due to acute hemorrhoidal attack between 2 groups: treated with placebo versus treated with Detralex.;Secondary Objective: Reduction of the other signs and symptoms of acute hemorhoidal attack.;Primary end point(s): The global efficacy of the treatment will be evaluated on the following main criteria: - Bleeding : reduction of bleeding, time to stop of bleeding (evaluation by investigator using a four point rating scale : NO, YES and if YES - 1=soiling, 2=blood on paper by wiping, 3=blood on feces, toilet bowl) - anitis : bulging, blush, warming, pain, impaired function (evaluation by investigator after anoscopy using a four point rating scale : 1=absent, 2=mild, 3=moderate, 4=severe) - pain (evaluation by the patient using a Visual Analogue Scale)

Countries

Czech Republic

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026